Posts Tagged ‘ipilimumab’

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Posted by • November 2nd, 2016

Oncologists and patients with cancer eagerly await new therapies that efficiently target cancer and avoid damage to normal tissues. In 2015, a randomised controlled trial investigated the role of two immune checkpoint inhibitors: ipilimumab — an anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody — and nivolumab — an anti-programmed death-1 (PD-1) antibody. Patients with untreated metastatic… Read More…

Anti–PD-L1 Antibody in Patients with Advanced Cancer

Posted by • June 27th, 2012

In the late 19th century, surgical oncologist William Coley reported the story of a patient with a sarcoma whose disease had gone into complete remission following an untreated strep infection at the site of the tumor.  At the time, Coley – who had recently witnessed the death of a young patient of his own from… Read More…

Metastatic Melanoma

Posted by • August 20th, 2010

In the Original Article, Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, Hodi et al. report that patients with metastatic melanoma who received an antibody to CTLA-4 (ipilimumab) with or without a gp100 vaccine survived nearly 4 months longer than did those who received the gp100 vaccine alone. The World Health Organization (WHO) estimates that… Read More…